Article and Video CATEGORIES
Here is the first of the awaited podcasts from Dr. Natasha Leighl's presentation on "Highlights in Lung Cancer from 2012". Dr. Leighl is a longtime friend who is a lung cancer expert at Princess Margaret Hospital in Toronto, Ontario, Canada, and she covered a wide range of topics that represented promising developments in the field for the past year, some of which likely to lead to new treatment options for patients in the clinic over the next few years.
The first part of her talk covered new information on potential treatment options for patients with advanced NSCLC that has an activating EGFR mutation. Here's the video and audio versions of the podcast, along with the figures for it. (We're going to forgo the transcript, since it's a time-consuming process, and I don't think there's a major audience for it -- tell us if there's a clear need for the transcripts for these programs that we're not seeing).
[powerpress]
Dr. Leighl Highlights in LC 2012: Pt 1 EGFR Mutn Pos Audio Podcast
Dr. Leighl Highlights in LC 2012 Pt 1 EGFR Mutn Pos Figures
We've got more parts of her presentation waiting in the wings, so check back for more highlights in lung cancer soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…